[go: up one dir, main page]

WO2007100775A3 - Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations - Google Patents

Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations Download PDF

Info

Publication number
WO2007100775A3
WO2007100775A3 PCT/US2007/004959 US2007004959W WO2007100775A3 WO 2007100775 A3 WO2007100775 A3 WO 2007100775A3 US 2007004959 W US2007004959 W US 2007004959W WO 2007100775 A3 WO2007100775 A3 WO 2007100775A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
regulating
neurotransmitter systems
inducing
neurotransmitter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004959
Other languages
English (en)
Other versions
WO2007100775A2 (fr
Inventor
Alexander Michalow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP07751698A priority Critical patent/EP2001495A4/fr
Priority to AU2007221135A priority patent/AU2007221135A1/en
Priority to CA002643802A priority patent/CA2643802A1/fr
Priority to JP2008556468A priority patent/JP2009528289A/ja
Publication of WO2007100775A2 publication Critical patent/WO2007100775A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007100775A3 publication Critical patent/WO2007100775A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de régulation des systèmes neurotransmetteurs par induction d'une réponse de contre-adaptation. Selon l'un des modes de réalisation de l'invention, une méthode de régulation d'un neurotransmetteur comprend l'étape d'administration renouvelée d'un ligand pour un récepteur dans le système neurotransmetteur, le rapport de la demi-vie d'administration sur l'intervalle entre les administrations ne dépassant pas ½. Les méthodes de la présente invention peuvent être utilisées dans le cadre de nombreuses affections mentales, neurologiques et physiologiques indésirables.
PCT/US2007/004959 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations Ceased WO2007100775A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07751698A EP2001495A4 (fr) 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations
AU2007221135A AU2007221135A1 (en) 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations
CA002643802A CA2643802A1 (fr) 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations
JP2008556468A JP2009528289A (ja) 2006-02-27 2007-02-27 対抗適応を誘発することにより神経伝達物質系を調節する方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77719006P 2006-02-27 2006-02-27
US60/777,190 2006-02-27
US85818606P 2006-11-09 2006-11-09
US60/858,186 2006-11-09

Publications (2)

Publication Number Publication Date
WO2007100775A2 WO2007100775A2 (fr) 2007-09-07
WO2007100775A3 true WO2007100775A3 (fr) 2008-11-27

Family

ID=38459618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004959 Ceased WO2007100775A2 (fr) 2006-02-27 2007-02-27 Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations

Country Status (5)

Country Link
EP (1) EP2001495A4 (fr)
JP (1) JP2009528289A (fr)
AU (1) AU2007221135A1 (fr)
CA (1) CA2643802A1 (fr)
WO (1) WO2007100775A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021509A2 (fr) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methodes therapeutiques
ES2438020T3 (es) 2005-11-10 2014-01-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Composiciones y métodos para el tratamiento de adicciones y otros trastornos neuropsiquiátricos
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2168580B1 (fr) * 2007-06-22 2015-12-02 Toray Industries, Inc. Traitement ou prevention de la schizophrénie
WO2009109001A1 (fr) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Procédé de prévention et/ou de traitement d’une maladie, d’une condition ou d’un état associés à une fonction réduite des neurones dopaminergiques
CA2785056A1 (fr) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methodes et compositions pour le traitement de la detresse dysfonctionnelle et l'augmentation de la securite et de l'efficacite de medicaments specifiques
BR112012032076A2 (pt) 2010-06-16 2016-09-13 Univ Louisiana State composição farmacêutica, e, métodos para tratar um paciente que está sofrendo de um distúrbio e de uma doença neurodegenerativa
CN103313601B (zh) * 2010-06-29 2015-04-08 宾夕法尼亚大学理事会 salvinorin组合物及其用途
US11000505B2 (en) * 2010-06-29 2021-05-11 The Trustees Of The University Of Pennsylvania Salvinorin compositions and uses thereof
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
TWI600654B (zh) 2012-11-19 2017-10-01 艾姆公司 用於治療寄生蟲疾病之化合物及組合物
US20150352100A1 (en) * 2013-01-21 2015-12-10 Avant Derma Pte. Ltd. Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
WO2014117090A1 (fr) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzyme
CN104955483A (zh) 2013-01-30 2015-09-30 法莫斯医疗公司 用低剂量药剂治疗抑郁症和其它疾病
WO2014170351A1 (fr) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalméfène pour le traitement de patients atteints de trouble de l'humeur
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
WO2016195723A1 (fr) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Méthodes de traitement d'états médiés par la substance p
CN106008487B (zh) * 2015-12-31 2019-08-09 北京理工大学 一种二苯乙烯类衍生物及其制备方法
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
WO2019169113A1 (fr) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions et procédés pour le traitement de l'endométriose
BR112021009832A2 (pt) 2018-11-21 2021-08-17 Case Western Reserve University composições e métodos de modulação da atividade da desidrogenase de cadeia curta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
HUP0301833A3 (en) * 2000-07-19 2005-12-28 Bristol Myers Squibb Pharma Co Crf2 ligands in combination therapy
US6437093B1 (en) * 2000-11-28 2002-08-20 Milkhaus Laboratory, Inc. Methods of treatment comprising administration of Substance P
US7439264B2 (en) * 2002-02-08 2008-10-21 President And Fellows Of Harvard College Therapeutic compounds
EP1809104A4 (fr) * 2004-09-23 2009-04-29 Alexander Michalow Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONG X.G. ET AL.: "Alterations in the substance P-induced anti-nociception in the central nervous system of rats after morphine tolerance", NEUROSCIENCE LETTERS, vol. 381, no. 1-2, 10 June 2005 (2005-06-10), pages 47 - 50, XP004881632 *
KOOB ET AL., SCIENCE, vol. 278, 3 October 1997 (1997-10-03), pages 52 - 57, XP008130215 *
NESTLER E.J. ET AL.: "MOLECULAR AND CELLULAR BASIS OF ADDICTION", SCIENCE, vol. 278, 3 October 1997 (1997-10-03), pages 58 - 63, XP008037785 *
See also references of EP2001495A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Also Published As

Publication number Publication date
AU2007221135A1 (en) 2007-09-07
JP2009528289A (ja) 2009-08-06
EP2001495A4 (fr) 2010-12-08
CA2643802A1 (fr) 2007-09-07
EP2001495A2 (fr) 2008-12-17
WO2007100775A2 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007100775A3 (fr) Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations
WO2006034343A3 (fr) Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations
WO2007130865A3 (fr) Gestion de catastrophes comprenant l'utilisation d'une plate-forme de syndication améliorée
WO2006128692A3 (fr) Derives de 2-oxo-1-pyrrolidine
WO2008009415A3 (fr) Dérivés hétéroaryliques substitués
WO2007130547A3 (fr) Système et procédé de syndication de modules hors site
WO2009032737A3 (fr) Systèmes et procédés pour administrer un médicament
WO2007084793A3 (fr) Système et procédé de génération et de distribution de contenu personnalisé
WO2009063325A3 (fr) Méthodes et systèmes de traitement de maladies
EP2389897A3 (fr) Valve circulatoire, système et procédé
WO2006037016A3 (fr) Nouvelle therapie destinee au traitement de maladies cerebrales degeneratives chroniques et d'une lesion du systeme nerveux
EP2349406A4 (fr) Système de régulation automatique et procédé de régulation d'une anesthésie
WO2006084164A8 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2008070269A3 (fr) Procédés, logiciel et systèmes d'imagerie
IL192168A0 (en) System and methods for initiating, maintaining, and delivering personalized information by communication server
WO2008125999A3 (fr) Activation contrôlée de fonction
WO2006015259A3 (fr) Composes et compositions comme modulateurs de recepteurs steroides
WO2006127429A3 (fr) Donnees d'ecran a partage selectif
WO2006081279A3 (fr) Regulation de la liberation de medicament par la modification transitoire de microenvironnements locaux
WO2006002275A3 (fr) Catheters dotes de valves et de membranes permeables
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
WO2006058059A3 (fr) Procede et composition pour administrer un antagoniste du recepteur de nmda a un sujet
EP1808784A3 (fr) Procédé de création d'un lien symbolique pouvant être compatible avec le système de fichier, procédé et appareil d'accès au fichier ou répertoire en utilisant le lien symbolique
WO2007112366A3 (fr) Enrichissement de produits pour animaux à l'aide de resveratrol
WO2007072992A3 (fr) Preparation solide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008556468

Country of ref document: JP

Ref document number: 2643802

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007221135

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3610/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007221135

Country of ref document: AU

Date of ref document: 20070227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007751698

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200780015117.5

Country of ref document: CN